Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Christina Claus(Roche (Switzerland)), Claudia Ferrara(Roche (Switzerland)), Wei Xu(Roche (Switzerland)), Johannes Sam(Roche (Switzerland)), Sabine M. Lang(Roche (Switzerland)), Franziska Uhlenbrock(Department of Biomedicine Basel), R. Albrecht(Roche (Switzerland)), Sylvia Herter(Roche (Switzerland)), Ramona Schlenker(Roche (Switzerland)), Tamara Hüsser(Roche (Switzerland)), Sarah Diggelmann(Roche (Switzerland)), John Challier(Roche (Switzerland)), Ekkehard Mössner(Roche (Switzerland)), Ralf J. Hosse(Roche (Switzerland)), Thomas Höfer(Roche (Switzerland)), Peter Brünker(Roche (Switzerland)), Catherine Joseph(Roche (Switzerland)), Jörg Benz(Roche (Switzerland)), Philippe Ringler(University of Basel), Henning Stahlberg(University of Basel), Matthias E. Lauer(Roche (Switzerland)), Mario Perro(Roche (Switzerland)), Stanford Chen(Roche (Switzerland)), Christine Küttel(Roche (Switzerland)), Preethi Latha Bhavani Mohan(Roche (Switzerland)), Valeria Nicolini(Roche (Switzerland)), Martina Birk(Roche (Switzerland)), Amandine Ongaro(Roche (Switzerland)), Christophe Prince(Roche (Switzerland)), Reto Gianotti(Roche (Switzerland)), Gregory O. Dugan(Wake Forest University), Christopher T. Whitlow(Wake Forest University), Kiran Kumar Solingapuram Sai(Wake Forest University), David L. Caudell(Wake Forest University), Armando G. Burgos-Rodríguez(Caribbean University), J. Mark Cline(Wake Forest University), Michael Hettich(Roche (Switzerland)), Maurizio Ceppi(Roche (Switzerland)), Anna Maria Giusti(Roche (Switzerland)), Flavio Crameri(Roche (Switzerland)), Wouter H. P. Driessen(Roche (Switzerland)), Peter N. Morcos, Anne Freimoser–Grundschober(Roche (Switzerland)), Victor Levitsky(Roche (Switzerland)), Maria Amann(Roche (Switzerland)), Sandra Grau-Richards(Roche (Switzerland)), Thomas von Hirschheydt(Sonneberg Observatory), Stella Tournaviti(Sonneberg Observatory), Michael Mølhøj(Sonneberg Observatory), Tanja Fauti(Roche (Switzerland)), Viola Heinzelmann‐Schwarz(University Hospital of Basel), Volker Teichgräber(Roche (Switzerland)), Sara Colombetti(Roche (Switzerland)), Marina Bacac(Roche (Switzerland)), Alfred Zippelius(Department of Biomedicine Basel), Christian Klein(Roche (Switzerland)), Pablo Umaña(Roche (Switzerland))
Cited by 264Open Access
Abstract
T cells. FAP- and CD19-4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.
Related Papers
No related papers found
Powered by citation graph analysis